Indegene Ltd

Indegene Ltd

Indegene Ltd has received preliminary approval from the US District Court for a proposed class action settlement against its wholly-owned subsidiary, Indegene, Inc. The settlement framework provides for a maximum settlement fund of approximately USD 4.72 million, payment of USD 250 per eligible approved claim, and retention/reversion to the defendants of amounts not required to satisfy approved claims.

Indegene Ltd

Indegene Ltd has announced an investors and analysts meeting on August 24-25, 2026, to discuss unpublished price sensitive information. The meeting will be held online and in-person in Bengaluru, and the details are available on the company's website.

Indegene Ltd

Indegene Ltd has provided an update on a class-action lawsuit against its wholly-owned subsidiary, Indegene, Inc., related to alleged violations of the U.S. Telephone Consumer Protection Act, 1991. The company has substantially concluded negotiations on a definitive settlement agreement, which remains subject to execution by the relevant parties and approval of the U.S. District Court.

Indegene Ltd

Indegene Ltd held its 28th Annual General Meeting on August 13, 2026, through video conference, in accordance with Ministry of Corporate Affairs and SEBI circulars. The meeting was attended by the company's management, directors, and shareholders. The agenda included introductions by the directors, a review of the company's performance, and discussions on various topics.

Indegene Ltd

Indegene Ltd has appointed Ms. Jill Mary De Simone as an independent director of the company, effective January 22, 2026, for a term of 3 years.

Indegene Ltd

Indegene Ltd held its 28th Annual General Meeting (AGM) on August 13, 2026, through video conferencing. All resolutions were passed with the required majority. The company has made the voting results and the Scrutinizer's Report available on its website.

Indegene Ltd

Indegene Ltd has announced an investor and analyst meeting on August 19, 2026, in Mumbai, where company officials will discuss unpublished price-sensitive information.

Indegene Ltd

Indegene Ltd held its 28th Annual General Meeting (AGM) on August 13, 2026, through video conferencing. The meeting was attended by the Chairman, Executive Director, and CEO, as well as other key management personnel and statutory auditors. The company secretary briefed members on the e-voting process and the scrutinizer appointed to oversee it. The meeting concluded with the company secretary informing members that they could cast their votes during the meeting through the NSDL e-voting website.

Indegene Ltd

Indegene Ltd has informed investors and analysts of a meeting scheduled for August 17, 2026, to discuss unpublished price sensitive information. The meeting will be held in person with various mutual funds and investment firms. The company's website will also provide information on the meeting.

Indegene Ltd

Indegene Ltd has announced an investors and analysts meeting on 17th July 2026, where officials will meet with various mutual funds and investment firms in Mumbai. The meeting is subject to change and no unpublished price sensitive information will be shared.

Indegene Ltd

Indegene Ltd received a disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 from BPC Genesis Fund I-A SPV Limited, indicating a 2.986% stake acquisition in the company.

Indegene Ltd

Indegene Ltd received a disclosure under Regulation 29(2) of SEBI (SAST) Regulations, 2011, from BPC Genesis Fund I SPV Limited regarding the acquisition of 13,862,223 shares of Indegene Ltd, representing a 5.757% stake in the company. The acquisition was completed on August 6, 2026.

Indegene Ltd

Indegene Ltd has announced the transcript of its earnings conference call for the quarter ended June 30, 2026, highlighting the company's performance and industry trends in the pharma sector.

Indegene Ltd

Indegene Ltd has announced its financial results for the quarter ended June 30, 2026, with a net profit of ₹8,682.13 crore and a basic EPS of ₹20.65. The company has filed its quarterly financial results with the stock exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Indegene Ltd

Indegene Ltd has made the audio recording of its Q1 FY27 earnings call available on its website and IR portal.

Indegene Ltd

Indegene Ltd has announced its Q1 FY'27 results, showing a 39.7% YoY revenue growth in INR terms and 26.5% in USD. The company has expanded its active client base to 105, improved productivity with revenue per employee rising to $77K, and deepened client relationships with 12 customers generating more than $10 million in annual revenue each.

Indegene Ltd

Indegene Ltd announced its financial results for the quarter ended June 30, 2026, with revenue up 39.7% YoY and PAT up 45.9% QoQ. The company also crossed the 100-milestone in active clients and expanded its customer base in the $10M+ range.

Indegene Ltd

Indegene Ltd has submitted a Monitoring Agency Report for the quarter ended June 30, 2026, as required by SEBI regulations, detailing the utilization of the proceeds from its IPO.

Indegene Ltd

Indegene Ltd has announced the allotment of shares under its ESOP Scheme 2020, and has also approved its unaudited standalone and consolidated financial results for the quarter ended June 30, 2026. The company's trading window will reopen on August 3, 2026.

Indegene Ltd

Indegene Ltd has announced its unaudited financial results for the quarter ended June 30, 2026, with the Board of Directors approving the results and auditor's review report. The company has reported a total revenue of Rs. 413 million and a total loss after tax of Rs. 12 million for the quarter.